Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo.

[1]  M. Marberger,et al.  Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. , 2004, Urology.

[2]  C. Roehrborn,et al.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. , 2003, The New England journal of medicine.

[3]  C. Roehrborn,et al.  Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. , 2002, European urology.

[4]  M. Barry,et al.  Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. , 2002, Urology.

[5]  C. Roehrborn,et al.  Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. , 2001, Urology.

[6]  S. Kaplan,et al.  Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. , 2001, Urology.

[7]  M. Marberger,et al.  Prostate Volume and Serum Prostate–Specific Antigen as Predictors of Acute Urinary Retention , 2000, European Urology.

[8]  P. Boyle,et al.  Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. , 1999, Urology.

[9]  R. Roberts,et al.  Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. , 1999, The Journal of urology.

[10]  E. Rimm,et al.  Incidence rates and risk factors for acute urinary retention: the health professionals followup study. , 1999, The Journal of urology.

[11]  C. Roehrborn,et al.  Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. , 1999, Urology.

[12]  R. Roberts,et al.  Natural history of prostatism: risk factors for acute urinary retention. , 1997, The Journal of urology.

[13]  A L Gould,et al.  Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. , 1996, Urology.

[14]  M. Barry,et al.  Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? , 1995, The Journal of urology.

[15]  C G Chute,et al.  Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. , 1995, The Journal of urology.

[16]  J. Mcconnell,et al.  The pathophysiology of benign prostatic hyperplasia. , 1991, Journal of andrology.

[17]  P. Walsh,et al.  The development of human benign prostatic hyperplasia with age. , 1984, The Journal of urology.

[18]  B. Djavan,et al.  Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia. , 2005, Current opinion in urology.